- Home
- BOTJ vs GANX Comparison
BOTJ vs GANX Comparison
Compare BOTJ & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOTJ
- GANX
- Stock Information
- Founded
- BOTJ 1998
- GANX 2017
- Country
- BOTJ United States
- GANX United States
- Employees
- BOTJ N/A
- GANX N/A
- Industry
- BOTJ Major Banks
- GANX Biotechnology: Pharmaceutical Preparations
- Sector
- BOTJ Finance
- GANX Health Care
- Exchange
- BOTJ Nasdaq
- GANX Nasdaq
- Market Cap
- BOTJ 62.6M
- GANX 51.8M
- IPO Year
- BOTJ N/A
- GANX 2021
- Fundamental
- Price
- BOTJ $13.76
- GANX $1.69
- Analyst Decision
- BOTJ
- GANX Strong Buy
- Analyst Count
- BOTJ 0
- GANX 5
- Target Price
- BOTJ N/A
- GANX $8.20
- AVG Volume (30 Days)
- BOTJ 2.6K
- GANX 304.5K
- Earning Date
- BOTJ 08-05-2025
- GANX 08-07-2025
- Dividend Yield
- BOTJ 2.91%
- GANX N/A
- EPS Growth
- BOTJ N/A
- GANX N/A
- EPS
- BOTJ 1.45
- GANX N/A
- Revenue
- BOTJ $45,083,000.00
- GANX N/A
- Revenue This Year
- BOTJ N/A
- GANX N/A
- Revenue Next Year
- BOTJ N/A
- GANX N/A
- P/E Ratio
- BOTJ $9.48
- GANX N/A
- Revenue Growth
- BOTJ 4.72
- GANX N/A
- 52 Week Low
- BOTJ $11.56
- GANX $0.89
- 52 Week High
- BOTJ $17.05
- GANX $3.19
- Technical
- Relative Strength Index (RSI)
- BOTJ 43.25
- GANX 48.21
- Support Level
- BOTJ $13.30
- GANX $1.55
- Resistance Level
- BOTJ $13.95
- GANX $1.72
- Average True Range (ATR)
- BOTJ 0.23
- GANX 0.13
- MACD
- BOTJ -0.02
- GANX 0.00
- Stochastic Oscillator
- BOTJ 48.52
- GANX 40.24
About BOTJ Bank of the James Financial Group Inc.
Bank of the James Financial Group Inc is a bank holding company that provides retail and commercial banking, deposit services, lending services, mortgage brokerage services, and other banking services. The company provides a range of deposit services including checking accounts, savings accounts and other time deposits of various types, ranging from daily money market accounts to longer-term certificates of deposit. It offers various types of secured and unsecured consumer loans, including personal loans, lines of credit, overdraft lines of credit, automobile loans, installment loans, demand loans, and home equity loans. It operates three business segments community banking; mortgage banking, and investment advisory services.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.